92 related articles for article (PubMed ID: 24673609)
1. Open-label, single-arm, phase II study of enzastaurin in patients with follicular lymphoma.
Schwartzberg L; Hermann R; Flinn I; Flora D; Hsi ED; Hamid O; Shi P; Lin BK; Myrand SP; Nguyen TS; Dreyling M
Br J Haematol; 2014 Jul; 166(1):91-7. PubMed ID: 24673609
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ; Kahl BS; Vose JM; de Vos S; Laughlin M; Flynn PJ; Rowland K; Cruz JC; Goldberg SL; Musib L; Darstein C; Enas N; Kutok JL; Aster JC; Neuberg D; Savage KJ; LaCasce A; Thornton D; Slapak CA; Shipp MA
J Clin Oncol; 2007 May; 25(13):1741-6. PubMed ID: 17389337
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
4. A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer.
Grønberg BH; Ciuleanu T; Fløtten Ø; Knuuttila A; Abel E; Langer SW; Krejcy K; Liepa AM; Munoz M; Hahka-Kemppinen M; Sundstrøm S
Lung Cancer; 2012 Oct; 78(1):63-9. PubMed ID: 22917813
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open-label, noncomparative screening study of enzastaurin in adult patients with non-Hodgkin lymphomas.
Forsyth CJ; Gomez-Almaguer D; Camargo JF; Eliadis PE; Crespo-Solis E; Pereira J; Gutierrez-Aguirre CH; Rivas-Vera S; Roberson S; Lin B; Smith NV; Hamid O
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):398-403. PubMed ID: 23770158
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K;
Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754
[TBL] [Abstract][Full Text] [Related]
7. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study.
Kilburn LB; Kocak M; Decker RL; Wetmore C; Chintagumpala M; Su J; Goldman S; Banerjee A; Gilbertson R; Fouladi M; Kun L; Boyett JM; Blaney SM
Neuro Oncol; 2015 Feb; 17(2):303-11. PubMed ID: 25431212
[TBL] [Abstract][Full Text] [Related]
9. A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma.
Jourdan E; Leblond V; Maisonneuve H; Benhadji KA; Hossain AM; Nguyen TS; Wooldridge JE; Moreau P
Leuk Lymphoma; 2014 Sep; 55(9):2013-7. PubMed ID: 24180331
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Morschhauser F; Seymour JF; Kluin-Nelemans HC; Grigg A; Wolf M; Pfreundschuh M; Tilly H; Raemaekers J; van 't Veer MB; Milpied N; Cartron G; Pezzutto A; Spencer A; Reyes F; Dreyling M
Ann Oncol; 2008 Feb; 19(2):247-53. PubMed ID: 17906297
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
Noguera IR; Sun CC; Broaddus RR; Branham D; Levenback CF; Ramirez PT; Sood AK; Coleman RL; Gershenson DM
Gynecol Oncol; 2012 Jun; 125(3):640-5. PubMed ID: 22387451
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma.
de Vos S; Goy A; Dakhil SR; Saleh MN; McLaughlin P; Belt R; Flowers CR; Knapp M; Hart L; Patel-Donnelly D; Glenn M; Gregory SA; Holladay C; Zhang T; Boral AL
J Clin Oncol; 2009 Oct; 27(30):5023-30. PubMed ID: 19770386
[TBL] [Abstract][Full Text] [Related]
13. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
15. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Usha L; Sill MW; Darcy KM; Benbrook DM; Hurteau JA; Michelin DP; Mannel RS; Hanjani P; De Geest K; Godwin AK
Gynecol Oncol; 2011 Jun; 121(3):455-61. PubMed ID: 21414654
[TBL] [Abstract][Full Text] [Related]
16. A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.
Ghobrial IM; Moreau P; Harris B; Poon T; Jourdan E; Maisonneuve H; Benhadji KA; Hossain AM; Nguyen TS; Wooldridge JE; Leblond V
Clin Cancer Res; 2012 Sep; 18(18):5043-50. PubMed ID: 22879385
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Ribrag V; Tilly H; Casasnovas O; Bosly A; Bouabdallah R; Delarue R; Boue F; Bron D; Feugier P; Haioun C; Offner F; Coiffier B
Eur J Cancer; 2013 Mar; 49(4):904-10. PubMed ID: 23273434
[TBL] [Abstract][Full Text] [Related]
18. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Clément-Duchêne C; Natale RB; Jahan T; Krupitskaya Y; Osarogiagbon R; Sanborn RE; Bernstein ED; Dudek AZ; Latz JE; Shi P; Wakelee HA
Lung Cancer; 2012 Oct; 78(1):57-62. PubMed ID: 22809813
[TBL] [Abstract][Full Text] [Related]
20. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Czuczman MS; Vose JM; Witzig TE; Zinzani PL; Buckstein R; Polikoff J; Li J; Pietronigro D; Ervin-Haynes A; Reeder CB
Br J Haematol; 2011 Aug; 154(4):477-81. PubMed ID: 21707581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]